शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
FABTECHNSEFabtech Technologies Limited· Healthcare Equipment & SuppliesHighNeutral
Announced Mon, 2 Feb, 2026 · 18:52 IST

Fabtech Q3 FY26 results: Q3 net loss of Rs 5.68 cr; 9M revenue up 31.5%

Net loss reportedExceptional itemResults View source PDFExplain this filing

FABTECH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-5.9%Reaction day
₹163.56
prior close
₹154.15
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+3.7%-9.6% vs market
Medical Equipment & Supplies peers, median of 13sector+3.8%-9.7% vs sector

On the reaction day the stock moved 9.6 pts less than Nifty Microcap 250 and 9.7 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-6.0
10m
-8.0
15m
-7.2
30m
-3.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-5.9+3.7-9.6+3.8-9.7
Next day
-10.4+5.1-15.5+3.6-14.0
2d
-6.5+4.0-10.5+3.0-9.4
3d
-4.6+3.2-7.8+2.9-7.5
4d
+0.1+5.9-5.8+1.8-1.7
5d
+3.8+6.9-3.2+3.1+0.7
1w
+1.5+5.9-4.4+4.6-3.1
15d
-4.0+2.1-6.1+0.5-4.6
1m
-12.6-3.5-9.1-2.9-9.7
2m
-10.7-4.2-6.5-6.3-4.4
3m
+1.6+10.9-9.3+4.1-2.5
UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q3 and 9M FY26 unaudited results. Q3 revenue fell to Rs 62.76 cr from Rs 104.32 cr YoY; consolidated net loss of Rs 5.68 cr vs Rs 20.46 cr profit. 9M FY26 revenue up 31.5% to Rs 252.25 cr but PAT fell to Rs 16.30 cr from Rs 31.36 cr. 9M EPS at Rs 4.49 vs Rs 9.68. Exceptional gain of Rs 1.77 cr from subsidiary stake sale included. Risk Management Committee dissolved.

Likely market impact

Q3 loss and sharp PAT decline may pressure the stock despite strong 9M revenue growth.